RJA
MRNA icon

Raymond James & Associates’s Moderna MRNA Stock Holding History

Raymond James & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$10.8M Buy
162,074
+26,657
+20% +$2.45M 0.01% 1179
2024
Q2 		$16.1M Sell
135,417
-23,627
-15% -$2.99M 0.01% 888
2024
Q1 		$16.9M Buy
159,044
+4,602
+3% +$464K 0.01% 851
2023
Q4 		$15.4M Sell
154,442
-31,900
-17% -$2.68M 0.01% 853
2023
Q3 		$19.2M Buy
186,342
+31,423
+20% +$3.51M 0.02% 696
2023
Q2 		$18.8M Buy
154,919
+7,562
+5% +$1.01M 0.02% 723
2023
Q1 		$22.6M Sell
147,357
-21,134
-13% -$3.49M 0.02% 631
2022
Q4 		$30.3M Buy
168,491
+11,663
+7% +$1.91M 0.03% 496
2022
Q3 		$18.5M Sell
156,828
-56,302
-26% -$8.54M 0.02% 639
2022
Q2 		$30.4M Buy
213,130
+19,144
+10% +$2.74M 0.03% 458
2022
Q1 		$33.4M Buy
193,986
+21,143
+12% +$3.56M 0.03% 482
2021
Q4 		$43.9M Buy
172,843
+24,622
+17% +$7.2M 0.04% 426
2021
Q3 		$57M Buy
148,221
+1,105
+0.8% +$408K 0.05% 314
2021
Q2 		$34.6M Buy
147,116
+7,069
+5% +$1.26M 0.03% 463
2021
Q1 		$18.3M Buy
140,047
+49,381
+54% +$7.16M 0.02% 710
2020
Q4 		$9.47M Buy
90,666
+16,940
+23% +$1.71M 0.01% 987
2020
Q3 		$5.22M Sell
73,726
-40,660
-36% -$2.83M 0.01% 1197
2020
Q2 		$7.34M Buy
114,386
+85,597
+297% +$4.69M 0.01% 980
2020
Q1 		$862K Buy
28,789
+17,721
+160% +$408K ﹤0.01% 2083
2019
Q4 		$216K Sell
11,068
-2,174
-16% -$38.6K ﹤0.01% 3300
2019
Q3 		$211K Buy
13,242
+1,503
+13% +$22.2K ﹤0.01% 3226
2019
Q2 		$172K Sell
11,739
-3,231
-22% -$69.4K ﹤0.01% 3314
2019
Q1 		$305K Buy
+14,970
New +$278K ﹤0.01% 2970

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James & Associates's MRNA Position: Q3 2024 in Review

Raymond James & Associates increased its Moderna (MRNA) stake by 20% in Q3 2024, buying an estimated $2.45M and bringing the position to 162,074 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #1179.

Raymond James & Associates first reported a position in MRNA in Q1 2019 and has held it in 23 quarters since. The position peaked at $57M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Raymond James & Associates held 162,074 shares of Moderna worth $10.8M as of Q3 2024.
  • Raymond James & Associates bought 26,657 Moderna shares in Q3 2024, an estimated $2.45M.
  • Moderna made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1179 holding.
  • Raymond James & Associates first reported a position in Moderna in Q1 2019 and has held it in 23 quarters since.
  • Raymond James & Associates's Moderna position peaked at $57M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.